Abstract
A case of oral submucous fibrosis occurring in a 38 year old man is presented. This paper tells the aetiology, clinical presentation and treatment of oral submucous fibrosis. This case highlights the link between oral submucous fibrosis and the regular use of areca-nut known commonly as pan and the newer trans-cultural oral tobacco products. The case report underlines the danger that human face with products which are clearly targeted at them by the tobacco industry.
Highlights
Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits, were reviewed at a consensus workshop in Kuala Lumpur, Malaysia in 19941
Criteria and guidelines were proposed to define, describe and identify lesions such as submucous fibrosis (OSMF) which had been described three decades earlier by Pindborg and Sirsat[2] as a chronic insidious disease affecting any part of the oral cavity and may extend to the pharynx and the oesophagus, and may be preceded or associated with vesicle formation. It is always associated with juxta-epithelial inflammation and followed by fibro-elastic change of the lamina propria with epithelial atrophy leading to stiffness of the oral mucosa and causing trismus
Cases of OSMF have been reported in individuals of South Asian origin living outside the sub-continent but it is extremely rare in White populations[4]
Summary
Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits, were reviewed at a consensus workshop in Kuala Lumpur, Malaysia in 19941. Criteria and guidelines were proposed to define, describe and identify lesions such as submucous fibrosis (OSMF) which had been described three decades earlier by Pindborg and Sirsat[2] as a chronic insidious disease affecting any part of the oral cavity and may extend to the pharynx and the oesophagus, and may be preceded or associated with vesicle formation. It is always associated with juxta-epithelial inflammation and followed by fibro-elastic change of the lamina propria with epithelial atrophy leading to stiffness of the oral mucosa and causing trismus. The patient was prescribed metronidazole tablets 200 mg three times daily for 5 days and instructed to use chlorhexidine 0.2% as a mouthwash twice daily
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
